Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yuanhuadine is a natural daphnane-type diterpene orthoester isolated from the flower buds of *Daphne genkwa*. It has demonstrated potent anti-proliferative and anti-tumor activities, particularly in non-small cell lung cancer (NSCLC). The compound's mechanism of action involves the up-regulation of SerpinB2 (plasminogen activator inhibitor-2), which leads to the suppression of invadopodia-like structure protrusions and reduced invasiveness in cancer cells. Yuanhuadine has shown potential in overcoming acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) like gefitinib by modulating the urokinase plasminogen activator (uPA) system and elevating SerpinB2 levels, which are typically down-regulated in resistant cell lines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yuanhuadine.